Background: Anabolic androgenic steroids (AAS) are traditionally used for the treatment/control of various diseases; however, they are being used for non-therapeutic and indiscriminate purposes to enhance sports performance and physical appearance. This study aimed to assess the prevalence and associated factors of AAS use among professional competitors.
Methods: We conducted an observational cross-sectional survey in which an anonymous questionnaire was applied to professional athletes.
Results: The prevalence of AAS usage was 33.3%. Most users were male (74.2%), aged between 30 and 39 years (51.6%), with completed higher education (83.9%), and had been training for more than 5 years (77.4%); the primary motivation for AAS use was performance enhancement (77.4%). Individuals who were older ( < 0.05) and more experienced in competitions ( < 0.01) are more likely to use AAS. Testosterone was the most employed AAS (71.0%); athletes typically used an average of 2 different AAS. The majority of users had notably sought advice from a physician (74.2%), and AAS were acquired from either drugstores (80.6%) or through illicit channels (29.0%). Moreover, 61.3% of AAS users reported experiencing adverse effects.
Conclusions: Our results demonstrated a higher prevalence of AAS users among professional competitors in compared to the general population; older age and greater experience in official competitions were decisive factors for a greater inclination toward AAS use. A significant percentage of athletes seek drugs through illegal channels. Despite the majority of users experiencing adverse effects, athletes report satisfaction with use, believing that the benefits still outweigh the drawbacks.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10826084.2024.2359717 | DOI Listing |
Theranostics
January 2025
Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Bone metastasis and skeletal-related complications are primary causes of mortality in advanced-stage prostate cancer (PCa). Epigenetic regulation, particularly histone modification, plays a key role in this process; however, the underlying mechanisms remain elusive. In mouse models, JARID1D was an important mediator of both visceral and bone metastases.
View Article and Find Full Text PDFTransl Androl Urol
December 2024
Department of Pathology, Pediatric and Perinatal Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone. Sustanon, dissolved in peanut oil, is an AAS used by athletes to build muscle mass. This study aims to examine the effects of Sustanon on male reproductive health.
View Article and Find Full Text PDFEndocrinol Diabetes Metab
January 2025
Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, California, USA.
Context: Hyperandrogenism is a hallmark of polycystic ovary syndrome (PCOS), yet the androgen(s) responsible remain ambiguous. Recent studies have suggested that 11-oxygenated C steroids (11-oxyandrogens), specifically 11-ketotestosterone, may be a good marker for hyperandrogenism in PCOS.
Objective: To investigate the utility of 11-oxyandrogens to differentiate women with and without PCOS relative to classical androgens.
Sci Rep
January 2025
Department of Emergency Medicine, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Changsha, Hunan, China.
Our study aims to investigate the role of pyrimidine metabolism in prostate cancer and its associations with the immune microenvironment, drug sensitivity, and tumor mutation burden. Through transcriptomic and single-cell RNA sequencing analyses, we explored metabolic pathway enrichment, immune infiltration patterns, and differential gene expression in prostate cancer samples. The results showed that pyrimidine metabolism-related genes were significantly upregulated in the P2 subgroup compared to the P1 subgroup, with enhanced metabolic activity observed in basal and luminal epithelial cells.
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Backgroud: Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over-expression.
Case: We report the case of a 64-year-old female with extra- and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan-Erb2 receptor tyrosine kinase inhibitor.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!